Aarti Pharmalabs Ltd - Q1 FY27 Earnings Call Summary Monday, August 10, 2026 · 4:00 PM IST
Event Participants
Executives
2 Rashesh Gogri (Chairman), Piyush Lakhani (CFO)
Analysts
11 Abhishek (Padmaja Investments), Ankit Gupta (Bamboo Capital), Ashish (Leo Capital), Julie Mehta (361 Capital Markets), Kunal Mehta (AMC), Prateesh Shetha (Lucky), Rahul Jain (Credence Wealth), Raj Agarwal (Nivesh Asset Management), Shubham Aggarwal (Burman Capital), Shubh Mehta (ICICI Securities), Vanan Desai (Total Capital)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹535 crores | +42% YoY vs ₹375 crores; driven by exceptional xanthine pricing and volume growth |
| EBITDA | ₹133 crores | +40% YoY vs ₹95 crores; margin at 24.9%, at upper end of guided 22-25% range |
| PAT | ₹71 crores | +49% YoY vs ₹48 crores |
| Xanthine Revenue | ~₹305 crores (57% of revenue) | Highest ever quarterly sales; 74% beverage customers / 26% others; 79% export / 21% domestic |
| API & Intermediates Revenue | ~₹160 crores (30% of revenue) | Impacted by ~6-week shutdown for steroid block debottlenecking; 58% regulated, 14% RoW, 28% non-regulated |
| CDMO-CMO Revenue | ~₹37 crores (7% of revenue) | 22 customers, 57 active projects (37 commercial, 20 development); H2-weighted year expected |
| Gross Margin | ~50-56% (quarter) | Elevated due to low-cost inventory sold at higher prices; normalized ~50% |
| Xanthine Production Capacity | 9,500 MT (from ~6,000 MT) | +50% capacity expansion commissioned; target >80% utilization by FY28 |
Geographic & Segment Commentary
Xanthine Derivatives (57% of revenue): Record quarter with ₹305 crores revenue. Volume grew ~25% YoY. Pricing remains elevated above pre-war levels despite easing from peak. China rebate removal is structurally supportive of pricing. Management targeting 20-25% global market share within 2 years; company now has second-largest xanthine capacity globally. Mix shifting toward beverage (cola) customers.
API & Intermediates (30% of revenue): Revenue of
₹160 crores was impacted by a 1.5-month shutdown for steroid block debottlenecking at Unit 4, Tarapur (USFDA-approved). Pricing pressures persist in existing molecules; process intensification project underway to reduce costs. Anti-cancer block debottlenecking planned for new launches next year. FY25-level revenue (₹780 crores) nearly achievable but not expected to be crossed.CDMO-CMO (7% of revenue): Revenue contribution lower but management confident in 40-50% growth guidance. 37 commercial projects (up from 21 three years ago) provide strong growth visibility. Revenue will be H2-skewed; new Attali Block 2 dedicated block (₹149 crores capex, 400+ KL) for 3-4 mature projects. Business has grown ~10x over 5.5 years, evolving from KSM supply to GMP API supply for tox/clinical batches.
Company-Specific & Strategic Commentary
Capacity Expansion: Q1 FY27 marks completion of steroid debottlenecking (Unit 4, Tarapur — +33% capacity), commercialized xanthine brownfield expansion (6,000→9,500 MT, trial production ongoing), and Attali Block 1 (440 KL) becoming fully operational in Q2 FY27.
Capital Allocation — CDMO: Announced ₹149 crores capex for Attali Block 2 (400+ KL, expandable by 200 KL) dedicated to specific CDMO projects — more cost-effective than multipurpose blocks. Civil works readiness for additional 200 KL expansion. Total CDMO-related capex ₹600+ crores targeting asset turnover of ~1x and ₹1,000 crores CDMO revenue goal (FY29-FY30).
Talent & R&D: Hired CSO, CTO, and segment CEOs; 250+ scientists across 3 R&D centers (Navi Mumbai innovation center with 100+ scientists, Dombivali API R&D, Vapi scale-up R&D). New capabilities in peptides and oligonucleotides; geographically distributed BD teams (Europe, US, Japan).
Cost Optimization: Process intensification and cost reduction special project initiated for existing API molecules to mitigate pricing pressure; xanthine capacity ramp-up expected to dilute fixed costs.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin (Standalone) | 22-25% for FY27 | Dependent on pace of operationalizing expanded capacities; CDMO ramp-up (higher margin) to support |
| CDMO-CMO Growth | 40-50% growth in FY27 | Confident; H2-heavy revenue profile; 37 commercial projects underpinning visibility |
| Xanthine Revenue | ₹900-1,100 crores for FY27 | Range depends on commodity price normalization; Q1 exceptional, pricing already easing |
| Xanthine Capacity Utilization | >80% by FY28 | New capacity of 9,500 MT being ramped up through next few quarters |
| Global Market Share (Xanthine) | 20-25% within next 2 years | Enhanced capacity positions company as second-largest global producer |
| CDMO Revenue Target | ₹1,000 crores by FY29 or FY30 | Supported by existing + new dedicated blocks; all 3 segments targeted to cross ₹1,000 crores |
| API Revenue | ~₹170-190 crores quarterly run-rate | Normalized from shutdown impact; anti-cancer launches next year; no further capex needed for ₹1,000 crores+ |
| Gross Margin (Company) | ~50% sustainable | CDMO commercial small molecule gross margins at 60-65%; API at 45-50% |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Middle East crisis drove raw material prices up 50-100% at peak, now eased to 25-50% above normal. Pass-through to customers skews EBITDA margins. Management attributes ~50% of current price increases as temporary. |
| Xanthine Price Normalization | Spot prices declining from peak; Q1 exceptional top-line unlikely to sustain. Management guided ₹900-1,100 crores range for FY27 — a wide band reflecting uncertainty. |
| Chinese Competition | China remains dominant with 80-90% of xanthine capacity. However, export rebate removal and production quotas are structurally supportive. Trade policy reversal remains a risk. |
| Pre-Operative Expenses Drag | Attali Block 1 and xanthine L99 site expenses to hit P&L from Q2 onwards; could pressure H1 margins before volumes ramp up. |
| API Pricing Pressure | Continued erosion in existing molecules; mitigation through process intensification and new launches (anti-cancer, anti-diabetic) with medium-term patent expiries. |
| CDMO Revenue Lumpiness | H2-heavy profile creates quarterly volatility; any project delays could shift revenue trajectory. Management cited accounting-standard-related postponement of some Q1 sales. |
Q&A Highlights
Xanthine Business Dynamics
Question: What is the domestic vs. export split, global market share, and competitive landscape in xanthine? (Dru, Vyomara Capital)
Answer: Export is 79% and domestic 21%; split will remain export-heavy as capacity ramps. Targeting 20-25% global market share within 2 years. China holds 80-90% of global xanthine capacity, making it the primary competitor. (Rashesh Gogri)
Question: What is the volume vs. realization growth in xanthine? (Raj Agarwal, Nivesh Asset Management)
Answer: Volume grew ~25% YoY. Realizations were elevated due to the Middle East crisis but have started declining — realization per kg will decline while overall sales grow with additional capacity. (Rashesh Gogri)
Question: How much of the current price increase is structural vs. temporary? (Shubham Agarwal, Burman Capital)
Answer: Roughly 50-50 split. The China export rebate removal is a structural, multi-year change; raw material increases tied to the West Asia crisis are temporary. Quota tightening in China is structurally improving industry margins. (Rashesh Gogri)
Margin Sustainability
Question: Is the 56% gross margin and 25.4% EBITDA margin sustainable? (Ankit Gupta, Bamboo Capital)
Answer: Absolute gross margin should sustain as higher volumes offset price normalization. Company operating at ~6,000 MT; new capacity of 9,500 MT will drive higher sales. Management reiterates 22-25% EBITDA guidance for FY27. (Rashesh Gogri)
Question: What is the sustainable gross margin range? (Yash Doshi, Unifi Capital)
Answer: Gross margin ~50% plus/minus few percentage points; company-level EBITDA margin in 20-25% range. CDMO commercial small-molecule gross margins at 60-65%; API at 45-50%. (Rashesh Gogri)
CDMO Strategy and Capacity
Question: Is the ₹149 crore dedicated block based on customer commitments or internal visibility? (Shubham Aggarwal, Burman Capital)
Answer: Block will serve 3-4 projects across multiple customers with good visibility. Dedicated design is more cost-effective than multipurpose — tailored to specific process needs. Won't comment on per-molecule revenue potential. (Rashesh Gogri)
Question: How should we think about CDMO gross margins as the business scales toward ₹1,000 crores? (Unidentified, Aarti Pharmalabs participant)
Answer: Not expecting 70-75% gross margins in small molecules; company at 60-65% on commercial side. Higher margins possible if moving into peptides/oligonucleotides. CDMO should exceed 25-30% of company sales as all segments cross ₹1,000 crores. (Rashesh Gogri)
API Business Outlook
- Question: Can API revenue recover to ₹200 crores quarterly run-rate? (Ankit Gupta, Bamboo Capital)
- Answer: Q1 was impacted by shutdown for steroid debottlenecking — normalized run-rate should be ₹170-190 crores. Anti-cancer block debottlenecking and new anti-diabetic product ramps will support growth. No additional capex needed for ₹1,000 crores+ API revenue. (Rashesh Gogri)
Gross Margin Impact Timing
- Question: When will pre-operative expenses hit the P&L? (Raj Agarwal, Nivesh Asset Management)
- Answer: Attali Block 1 expenses will start hitting from Q2 FY27; xanthine L99 site trial production started end-June with expenses from current quarter. Management sees no significant P&L hit as capacity ramp-up offsets increased costs. (Rashesh Gogri)
Key Takeaway
Aarti Pharmalabs delivered a record Q1 FY27 with revenue of ₹535 crores (+42% YoY), driven by exceptional xanthine pricing and 25% volume growth amid the West Asia crisis and structural Chinese rebate removal. The company completed multiple expansions — steroid debottlenecking (+33% capacity), xanthine brownfield expansion to 9,500 MT, and Attali Block 1 nearing full operational status — with a new ₹149 crores dedicated CDMO block announced to support the ₹1,000 crores CDMO revenue ambition. Management guided 40-50% CDMO growth with H2-heavy revenue, FY27 EBITDA margins of 22-25%, and xanthine revenue of ₹900-1,100 crores. Key watch points include xanthine price normalization (currently 25-50% above pre-war levels), pre-operative expense drag in H1, and API pricing pressure mitigation through process intensification and anti-cancer launches. The strategy focuses on scaling all three segments toward ₹1,000 crores each, leveraging structural improvements in xanthine economics and maturing CDMO commercial portfolio of 37 projects.